Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1973 1
1977 1
1978 1
1979 2
1980 2
1981 2
1982 3
1983 4
1984 3
1985 2
1986 7
1987 6
1988 4
1989 9
1990 11
1991 4
1992 7
1993 8
1994 12
1995 14
1996 4
1997 15
1998 13
1999 10
2000 11
2001 9
2002 22
2003 21
2004 19
2005 24
2006 18
2007 27
2008 33
2009 25
2010 23
2011 36
2012 43
2013 46
2014 50
2015 54
2016 71
2017 70
2018 79
2019 69
2020 70
2021 66
2022 61
2023 54
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

999 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypertrophic cardiomyopathy 15"
Page 1
Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.
Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF, Appelbaum E, Desvigne-Nickens P, DiMarco JP, Friedrich MG, Geller N, Harper AR, Jarolim P, Jerosch-Herold M, Kim DY, Maron MS, Schulz-Menger J, Piechnik SK, Thomson K, Zhang C, Watkins H, Weintraub WS, Kramer CM; HCMR Investigators. Neubauer S, et al. J Am Coll Cardiol. 2019 Nov 12;74(19):2333-2345. doi: 10.1016/j.jacc.2019.08.1057. J Am Coll Cardiol. 2019. PMID: 31699273 Free PMC article.
BACKGROUND: The HCMR (Hypertrophic Cardiomyopathy Registry) is a National Heart, Lung, and Blood Institute-funded, prospective registry of 2,755 patients with hypertrophic cardiomyopathy (HCM) recruited from 44 sites in 6 countries. OBJECTIVES: The aut …
BACKGROUND: The HCMR (Hypertrophic Cardiomyopathy Registry) is a National Heart, Lung, and Blood Institute-funded, prospective …
Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers.
Lorenzini M, Norrish G, Field E, Ochoa JP, Cicerchia M, Akhtar MM, Syrris P, Lopes LR, Kaski JP, Elliott PM. Lorenzini M, et al. J Am Coll Cardiol. 2020 Aug 4;76(5):550-559. doi: 10.1016/j.jacc.2020.06.011. J Am Coll Cardiol. 2020. PMID: 32731933 Free PMC article.
BACKGROUND: Predictive genetic screening of relatives of patients with hypertrophic cardiomyopathy (HCM) caused by sarcomere protein (SP) gene mutations is current standard of care, but there are few data on long-term outcomes in mutation carriers without HCM …
BACKGROUND: Predictive genetic screening of relatives of patients with hypertrophic cardiomyopathy (HCM) caused by sarc …
Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations.
Coppini R, Ho CY, Ashley E, Day S, Ferrantini C, Girolami F, Tomberli B, Bardi S, Torricelli F, Cecchi F, Mugelli A, Poggesi C, Tardiff J, Olivotto I. Coppini R, et al. J Am Coll Cardiol. 2014 Dec 23;64(24):2589-2600. doi: 10.1016/j.jacc.2014.09.059. J Am Coll Cardiol. 2014. PMID: 25524337 Free PMC article.
BACKGROUND: Mild hypertrophy but increased arrhythmic risk characterizes the stereotypic phenotype proposed for hypertrophic cardiomyopathy (HCM) caused by thin-filament mutations. ...
BACKGROUND: Mild hypertrophy but increased arrhythmic risk characterizes the stereotypic phenotype proposed for hypertrophic cardi …
Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation.
Thompson AD, Helms AS, Kannan A, Yob J, Lakdawala NK, Wittekind SG, Pereira AC, Jacoby DL, Colan SD, Ashley EA, Saberi S, Ware JS, Ingles J, Semsarian C, Michels M, Mazzarotto F, Olivotto I, Ho CY, Day SM. Thompson AD, et al. Genet Med. 2021 Jul;23(7):1281-1287. doi: 10.1038/s41436-021-01134-9. Epub 2021 Mar 29. Genet Med. 2021. PMID: 33782553 Free PMC article.
PURPOSE: Variants in MYBPC3 causing loss of function are the most common cause of hypertrophic cardiomyopathy (HCM). However, a substantial number of patients carry missense variants of uncertain significance (VUS) in MYBPC3. ...METHODS: Among 7,963 patients in the …
PURPOSE: Variants in MYBPC3 causing loss of function are the most common cause of hypertrophic cardiomyopathy (HCM). However, …
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).
O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. O'Mahony C, et al. Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14. Eur Heart J. 2014. PMID: 24126876
AIMS: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. ...The aim of this study was to develop and validate a new SCD risk prediction model that provides individualized risk estimates. METHODS AND RESULTS: Th …
AIMS: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. ...The aim of this s …
Exercise and myocardial injury in hypertrophic cardiomyopathy.
Cramer GE, Gommans DHF, Dieker HJ, Michels M, Verheugt F, de Boer MJ, Bakker J, Fouraux MA, Timmermans J, Kofflard M, Brouwer M. Cramer GE, et al. Heart. 2020 Aug;106(15):1169-1175. doi: 10.1136/heartjnl-2019-315818. Epub 2020 Jan 30. Heart. 2020. PMID: 32001622 Free PMC article.
OBJECTIVE: Troponin and high signal intensity on T2-weighted (HighT2) cardiovascular magnetic resonance imaging (CMRi) are both markers of myocardial injury in hypertrophic cardiomyopathy (HCM). The interplay between exercise and disease development remains uncertai …
OBJECTIVE: Troponin and high signal intensity on T2-weighted (HighT2) cardiovascular magnetic resonance imaging (CMRi) are both markers of m …
Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy.
Liu J, Zhao S, Yu S, Wu G, Wang D, Liu L, Song J, Zhu Y, Kang L, Wang J, Song L. Liu J, et al. Radiology. 2022 Feb;302(2):298-306. doi: 10.1148/radiol.2021210914. Epub 2021 Nov 2. Radiology. 2022. PMID: 34726536
Background Myocardial replacement fibrosis is one of the major histologic features of hypertrophic cardiomyopathy (HCM), but its characteristics have not been well delineated. ...Cox analysis indicated that both the global extent of LGE (adjusted hazard ratio = 1.68 …
Background Myocardial replacement fibrosis is one of the major histologic features of hypertrophic cardiomyopathy (HCM), but i …
Management and outcomes of hypertrophic cardiomyopathy in young adults.
Baron É, Karam N, Donal E, Puscas T, Mirabel M, Bacher A, Wahbi K, Mazzella JM, Jeunemaitre X, Reant P, Hagège A; REMY, GEREMY working groups of the French Society of Cardiology. Baron É, et al. Arch Cardiovasc Dis. 2021 Jun-Jul;114(6-7):465-473. doi: 10.1016/j.acvd.2020.12.006. Epub 2021 Mar 17. Arch Cardiovasc Dis. 2021. PMID: 33744178 Free article.
BACKGROUND: Management of young adults with hypertrophic cardiomyopathy (HCM) is challenging. AIMS: To evaluate the profile of young adults (16-25 years) with HCM included in the French prospective HCM registry. ...
BACKGROUND: Management of young adults with hypertrophic cardiomyopathy (HCM) is challenging. AIMS: To evaluate the profile of …
Improved Diagnostic Criteria for Apical Hypertrophic Cardiomyopathy.
Hughes RK, Shiwani H, Rosmini S, Augusto JB, Burke L, Jiang Y, Pierce I, Joy G, Castelletti S, Orini M, Kellman P, Xue H, Lopes LR, Mohiddin S, Treibel T, Manisty C, Captur G, Davies R, Moon JC. Hughes RK, et al. JACC Cardiovasc Imaging. 2024 May;17(5):501-512. doi: 10.1016/j.jcmg.2023.07.012. Epub 2023 Oct 11. JACC Cardiovasc Imaging. 2024. PMID: 37831014
BACKGROUND: There is no acceptable maximum wall thickness (MWT) threshold for diagnosing apical hypertrophic cardiomyopathy (ApHCM), with guidelines referring to 15 mm MWT for all hypertrophic cardiomyopathy subtypes. ...
BACKGROUND: There is no acceptable maximum wall thickness (MWT) threshold for diagnosing apical hypertrophic cardiomyopathy (A …
Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension.
Luo Q, Chen J, Zhang T, Tang X, Yu B. Luo Q, et al. Sci Rep. 2020 Jan 15;10(1):349. doi: 10.1038/s41598-019-57230-z. Sci Rep. 2020. PMID: 31941943 Free PMC article.
We here studied the clinical features, cardiac structure, and functional changes and prognosis of hypertrophic cardiomyopathy (HCM) patients with hypertension (HTN). ...In conclusion, we found that the clinical phenotypes of HCM patients with HTN differed fro …
We here studied the clinical features, cardiac structure, and functional changes and prognosis of hypertrophic cardiomyopat …
999 results